Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
CosmosID logo — Unlocking The Microbiome

CosmosID

Unlocking The Microbiome

Founded 2008 United States Germantown, United States 30 employees Series B Total: $7.22M Biotechnology, Health Care

General Information

Company Name CosmosID
Founded Year 2008
Location United States Germantown, United States
Employees 30
Industries Biotechnology, Health Care
Funding Stage Series B
Business Model B2B, SaaS, Freemium
Revenue Model Service Fee, Freemium, Subscription
Social

BounceWatch is an independent company data service, not affiliated with CosmosID. To contact CosmosID, visit cosmosid.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About CosmosID

CosmosID, founded in 2008 by Dr. Rita Colwell, is a pioneering company in the Biotechnology and Health Care sectors, headquartered in the United States. The company’s slogan, "Unlocking The Microbiome", encapsulates its mission of providing comprehensive microbiome solutions through its advanced technological offerings.

CosmosID specializes in Next-Generation Sequencing (NGS), Metabolomics, and Bioinformatics, with its primary product being the CosmosID-HUB: Microbiome. This software is recognized for its award-winning capabilities, particularly its precision in delivering strain-level results which are essential for actionable insights in microbiology.

The company's last reported funding was a $6.00M Series B investment from the Applied Value Group in January 2016. CosmosID stands as a valuable prospect for investors seeking to capitalize on the increasing demand for microbiome analytical solutions that stress accuracy and depth.

Taxonomy: Microbiome, NGS, Metabolomics, Bioinformatics, Strain-level analysis, Infectious disease diagnostics, Public health surveillance, Food safety inspections, Pharmaceutical discovery, Health and wellness, Metagenomics, Genomics, Pathogen detection, Epidemiology, Next Gen Sequencing

Services & Products

Amplicon Sequencing
Shallow Shotgun Sequencing
Deep Shotgun Metagenomic Sequencing
Bacterial Isolate Sequencing
Bioinformatics Analysis

Target Customers

Healthcare Professionals Pharmaceutical Companies Academic Researchers Biotech Firms Clinicians

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $6.00M 1
Applied Value Group
Applied Value Group
27 Jan 2016
Venture Round $1.22M -
16 Aug 2011

CosmosID Alternatives & Competitors

CosmosID vs
Clear Labs
Clear Labs United States

Provider of fully automated next generation sequencing platforms, software and robotics for turnkey...

Series D
86 employees
AI, Biotechnology
CosmosID vs
TwinStrand Biosciences
TwinStrand Biosciences

Ultra-rare variants are detected with unparalleled sensitivity and specificity with TwinStrand Duple...

Venture round
24 employees
Biotechnology, Health Care
CosmosID vs
PathoQuest
PathoQuest France

A global CRO providing BioPharma Quality Control Testing based on GMP Next Generation Sequencing

Series B
59 employees
Biotechnology, Health Care

FAQ About CosmosID

Unlocking The Microbiome
CosmosID was founded in 2008.
CosmosID is headquartered in Germantown, United States.
CosmosID operates in Biotechnology and Health Care. Its work centres on Microbiome, NGS, Metabolomics and Bioinformatics. Its customers include Healthcare Professionals, Pharmaceutical Companies and Academic Researchers.
CosmosID has a B2B, SaaS and Freemium business model. Its revenue comes from Service Fee, Freemium and Subscription.
CosmosID has approximately 30 employees.
CosmosID has completed 2 funding rounds, raising a total of $7.22M. The latest funding stage is Series B.
CosmosID offers: Amplicon Sequencing, Shallow Shotgun Sequencing, Deep Shotgun Metagenomic Sequencing, Bacterial Isolate Sequencing, Bioinformatics Analysis.
Top alternatives and competitors to CosmosID include Clear Labs, TwinStrand Biosciences, PathoQuest, Pathogenetix, Inc., MEDGENOME. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
CosmosID and Clear Labs are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for CosmosID, https://bouncewatch.com/company/cosmosid, updated 18 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes